In preliminary studies using the HDAC inhibitors trichostatin A (TSA) and SAHA, we demonstrated significant anti-tumor activity in PDX models of high grade serous ovarian cancer. This evidence concerns the gene HDAC9 and ovarian serous adenocarcinoma.